Relieving Congestion in Acute Heart Failure (AHF) Patients.

ACUTE HEART FAILURE (AHF)

1M

HOSPITALIZED
ANNUALLY IN THE US

20-30%

SUFFER DELAYED OR POOR RESPONSE TO THERAPY

1in4

READMITTED
WITHIN 30 DAYS

AHF Background

Heart failure (HF) is a chronic, progressive disease in which the heart is unable to pump enough oxygen-rich blood to the body. Acute HF is the sudden worsening of this condition, mostly due to fluid congestion. Increase in blood volume elevates vascular pressure and affects the kidneys’ ability to exert urine and sodium, causing build-up in the extremities (edema), lungs (dyspnea), and other internal organs.

The key treatment is diuretic therapy, aimed at increasing the patient’s urine and sodium output.

Poor or delayed response to diuretics leads to increased mortality, longer hospitalization, and higher 30-day re-admission rates. This direct financial impact is not reimbursed to the hospitals, with potential added risk from The Affordable Care Act penalties.

Relieves congestion, restores organ function, enhances diuretic efficiency

The Doraya catheter is designed to improve the efficacy of diuretic therapy in patients with acute heart failure (AHF). A manageable flow-reducing Central Venus Catheter, Doraya is deployed in the infrarenal IVC for up to 12 hours, helping cardiologists to temporarily manage venous hemodynamics, central venous pressure, renal afterload, and venous returns. Initial data from the Doraya feasibility study were presented at PCR 2019 by Dr. Reit Dierckx (OLV, Aalst, Belgium), demonstrating promising results. 
To see the full presentation [download PDF].

The potential benefits of interventional decongestion

Improved diuretic
efficacy and urine output

Improved clinical signs
and symptoms
(edema, ascites, dyspnea)

Reduced length of
hospital stay

Reduced 30-day
readmissions

,,

ABOUT US

Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. We believe that by using Doraya, cardiologists can enhance patient response to diuretic therapy, thereby rapidly alleviate signs and symptoms of congestion, improving patient outcomes and significantly reducing the financial burden of readmission. Revamp has a seasoned team of professionals with a proven track record in leading multiple med-tech startups.

OUR TEAM

Lihu Avitov

CEO, Co-founder

holds a bachelor’s degree in Economics & Management and master’s degree in Industrial Engineering. For the last 20 years he has been involved in the medical device and investments industries. In his former position as CEO of Angioslide, a cardiovascular company with CE & FDA marketing approvals, he managed over 40 employees in Israel, Germany and US. Angioslide delivered thousands of catheters to global markets, and had commercial partners in US, EU, China and India. Additional positions included EVP and XT Ventures and CEO of Naiot Accelerator. In addition to his role as Revamp CEO, Lihu provides consulting service to Agate VC and is a board member at YEDA (Weitzman Institute TT company).

Rafi Benary

CTO, Co-founder

holds a Masters’ degree from the New York University in Material Science and a Mechanical Engineering. He is an entrepreneur of 4 start-up companies, bringing them from inception to clinical stage through effective planning and execution. Rafi has more than 20 years of experience in the medical device field. His former positions: Co-founder at Ventor Technologies and Pi-Cardia, founding CEO and CTO at EndoSpan.  Ventor, developing an innovative cardiac valve catheter, was sold to Medtronic in 2013, for $300M. Both Pi-Cardia and EndoSpan have partnered with strategic commercial partners prior to initiating sales.

Yael Shohat

COO

holds a Master’s degree in biomedical engineering from the Technion University. She has vast experience in management of project timelines and budget; transferring the projects from development to production; preparation and execution of V&V, matrix management of project engineers. Yael has over a decade of R&D experience as a project manager in the development of the most challenging projects in the cardiac area. She has worked for innovative cardio related companies such as: CorAssist, V-Wave and EndoCross.

Simona Beilin-Nissan

Clinical Director

holds a Bachelor’s degree in Biotechnology and Food Engineering and a Master’s degree in Biomedical Engineering both from the Technion University. Simona has gained expertise in development, pre-clinical & clinical stages of cardiovascular devices for the last 18 years. She has worked in the companies, such as: Radbiomed, BBA, Novogate Medical, EndoSpan and Topspin Medical.  

Clinical / Scientific Advisory Board

Dr. Gerasimos Filippatos (Athens)

President of the Heart Failure Association (HFA) of the ESC, served as Chair of the Clinical Section and the Committee on AHF of the HFA, and as Chair of the ESC’s Working Group on Acute Cardiac Care. Published over 400 articles and the author of AHF chapter in Braunwald.

Dr. Ulrich Jorde (New York)

Section Head, Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support, Montefiore MC, NY. Serves as Chair of the Mechanical Circulatory Support Council of the International Society of Heart and Lung Transplantation.

Dr. Piotr Ponikowski (Wroclaw)

Head of the Cardiology Department at the Centre for Heart Diseases at the 4th Military Hospital, Wroclaw, Poland. He was the committee chairman of the ESC Guidelines on the Diagnosis and Treatment of Acute and Chronic Heart Failure (2016).

CONTACT US

Revamp Medical Ltd. 5 Mefi, Netania, Israel, 4250489
T: +972-73-3819227 | info@revampmedical.com

This project has received funding from the European Union’s Horizon 2020 SME Instrument program under grant agreement nr 855362.